All news

© Getty Images

Intellegens and CPI awarded £1.6m Innovate UK grant

By Isabel Cameron

Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, to apply ML in the emerging field of oligonucleotide therapies.

© Getty Images

Q&A: The potential of immuno-oncology - a view from the R&D department

By Isabel Cameron

Cancer immunotherapy, more commonly known as immuno-oncology, continues to gather momentum. As a rapidly evolving field, ongoing research and advancements are coming together to expand the number of available treatments, many of which are showing incredible...

© Getty Images

J&J’s Akeega FDA approval to heat up PARP battle

By Isabel Cameron

The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC).

© Getty Images

New appointments: Who are the movers and shakers in pharma?

By Isabel Cameron

BioPharma Reporter and Outsourcing Pharma presents its latest round-up of the movers and shakers in the pharma industry. From Karuna Therapeutics to IO Biotech, we break down the key changes on the pharmaceutical job ladder.

© Getty Images

Genprex bags FDA orphan drug designation for lung cancer therapy

By Isabel Cameron

Genprex has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead candidate, Reqorsa immunogene therapy (quaratusugene ozeplasmid), for the treatment of small cell lung cancer (SCLC).

Follow us

Webinars